What is the evidence for the use of second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder?

Nordic Journal of Psychiatry

Volumn 68, Issue 4, 2014, Pages 227-235

  Samalin, Ludovic ^a,b   Nourry, Aurore ^a   Charpeaud, Thomas ^a   Llorca, Pierre Michel ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

Antipsychotics; Bipolar disorder; Long acting injection; Maintenance treatment

Indexed keywords

ARIPIPRAZOLE; MOOD STABILIZER; OLANZAPINE; PALIPERIDONE; PLACEBO; RISPERIDONE;

BIPOLAR DISORDER; BIPOLAR I DISORDER; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MONOTHERAPY; REVIEW;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DELAYED-ACTION PREPARATIONS; EVIDENCE-BASED MEDICINE; HUMANS; INJECTIONS, INTRAVENOUS; LONG-TERM CARE; MEDICATION ADHERENCE; RECURRENCE; RISPERIDONE;

EID: 84899077301     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2013.801078     Document Type: Review

References (40)

1. Rainer MK. Risperidone long-acting injection: A review of its long term safety and efficacy. Neuropsychiatr Dis Treat 2008;4: 919-27.
2. Gutierrez-Rojas L, Jurado D, Martinez-Ortega JM, Gurpegui M. Poor adherence to treatment associated with a high recurrence in a bipolar disorder outpatient sample. J Affect Disord 2010;127: 77-83.
3. Hassan M, Lage MJ. Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge. Am J Health Syst Pharm 2009;66: 358-65.
4. El-Hage W, Surguladze SA. Emerging treatments in the management of bipolar disorder - Focus on risperidone long acting injection. Neuropsychiatr Dis Treat 2010;6: 455-64.
5. Samalin L, Charpeaud T, Lorabi O, Llorca P. Patient perspectives on use of long-acting antipsychotics in bipolar disorder: Focus on risperidone injection. Patient Prefer Adherence 2010;4: 325-34.
6. Haute Autorité de Santé [Internet]. Guide d'analyse de la litt é rature et gradation des recommandations [updated 2000 Jan 1]. Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/ analiterat.pdf
7. Clinical Trials.gov [Internet]. Paliperidone palmitate efficacy and safety in bipolar disorder complicated by alcohlism [updated 2010 Sep]. Available from: http://clinicaltrials.gov/ct2/show/NCT01211704?term- paliperidone-bipolar & rank- 1
8. Clinical Trials.gov [Internet]. Efficacy, safety, and tolerability of an intramuscular formulation of aripiprazole (OPC-14597) as maintenance treatment in bipolar I patients [updated 2012 Oct 17]. Available from: http://clinicaltrials.gov/ct2/show/NCT01567527? term -aripiprazole-depot-bipolar & rank-1
9. W, Alphs L, Haskins JT, Turner N, Turkoz I, Bossie C, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 2009;11: 827-39.
10. Quiroz JA, Yatham LN, Palumbo JM, Karcher K, Kushner S, Kusumakar V. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010;68: 156-62.
11. Vieta E, Montgomery S, Sulaiman AH, Cordoba R, Huberlant B, Martinez L, et al. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol 2012;22: 825-35.
12. Yatham LN, Fallu A, Binder CE. A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder. Acta Psychiatr Scand 2007;Suppl 434: 50-6.
13. Bobo WV, Epstein RA, Lynch A, Patton TD, Bossaller NA, Shelton RC. A randomized open comparison of long-acting injectable risperidone and treatment as usual for prevention of relapse, rehospitalization, and urgent care referral in community-treated patients with rapid cycling bipolar disorder. Clin Neuropharmacol 2011;34: 224-33.
14. Benabarre A, Castro P, Sanchez-Moreno J, Martinez-Aran A, Salamero M, Murru A, et al. Efficacy and safety of long-acting injectable risperidone in maintenance phase of bipolar and schizoaffective disorder. Actas Esp Psiquiatr 2009;37: 143-7.
15. Savas HA, Yumru M, Ozen ME. Use of long-acting risperidone in the treatment of bipolar patients. J Clin Psychopharmacol 2006;26: 530-1.
16. Vieta E, Nieto E, Autet A, Rosa AR, Goikolea JM, Cruz N, et al. A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone. World J Biol Psychiatry 2008;9: 219-24.
17. Han C, Lee MS, Pae CU, Ko YH, Patkar AA, Jung IK. Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31: 1219-23.
18. Malempati RN, Bond DJ, Kunz M, Malemati C, Cheng A, Yatham LN. Long-term efficacy of risperidone long-acting injectable in bipolar disorder with psychotic features: A prospective study of 3-year outcomes. Int Clin Psychopharmacol 2011;26: 146-50.
19. Malempati RN, Bond DJ, Yatham LN. Depot risperidone in the outpatient management of bipolar disorder: A 2-year study of 10 patients. Int Clin Psychopharmacol. 2008;23: 88-94.
20. Macfadden W, Adler CM, Turkoz I, Haskins JT, Turner N, Alphs L. Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms. BMC Psychiatry 2011;11: 1-10.
21. Food and Drug Administration [Internet]. Risperdal Consta: Full Prescribing Information [updated 2011 Sep]. Available from: http://www. accessdata.fda.gov/drugsatfda-docs/label/2011/020272s060s0 66,020588s048s054, 021444s035s042lbl.pdf
22. Samalin L, Charpeaud T, Blanc O, Heres S, Llorca P. Clinicians' attitudes toward the use of long-acting injectable antipsychotics. J Nerv Ment Dis 2013;201: 553-9.
23. Chue P, Chue J. The cost-effectiveness of risperidone long-acting injection in the treatment of schizophrenia. Expert Rev Pharmacoecon Outcomes Res 2012;12: 259-69.
24. Grimaldi-Bensouda L, Rouillon F, Astruc B, Rossignol M, Benichou J, Falissard B, et al. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res 2012;134: 187-94.
25. Sajatovic M, Biswas K, Kilbourne AK, Fenn H, Williford W, Bauer MS. Factors associated with prospective long-term treatment adherence among individuals with bipolar disorder. Psychiatr Serv 2008;59: 753-9.
26. Coryell W. Rapid cycling bipolar disorder: Clinical characteristics and treatment options. CNS Drugs 2005;19: 557-69.
27. Degenhardt EK, Gatz JL, Jacob J, Tohen M. Predictors of relapse or recurrence in bipolar I disorder. J Affect Disord 2012;136: 733-9.
28. Garcia-Amador M, Colom F, Valenti M, Horga G, Vieta E. Suicide risk in rapid cycling bipolar patients. J Affect Disord 2009;117: 74-8.
29. Eaddy M, Grogg A, Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 2005;27: 263-72.
30. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010;11: 81-109.
31. Malhi GS, Adams D, Lampe L, Paton M, O'Connor N, Newton LA, et al. Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand 2009;Suppl 439: 27-46.
32. Bond DJ, Pratoomsri W, Yatham LN. Depot antipsychotic medications in bipolar disorder: A review of the literature. Acta Psychiatr Scand 2007;Suppl 434: 3-16.
33. Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009;10: 85-116.
34. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2009. Bipolar Disord 2009;11: 225-55.
35. Henry C, Etain B. New ways to classify bipolar disorders: Going from categorical groups to symptom clusters or dimensions. Curr Psychiatry Rep 2010;12: 505-11.
36. Coryell W, Leon AC, Turvey C, Akiskal HS, Mueller T, Endicott J. The significance of psychotic features in manic episodes: A report from the NIMH collaborative study. J Affect Disord 2001;67: 79-88.
37. Dsm5.org [Internet]. Bipolar and related disorders [updated 2012 May]. Available from: http://www.dsm5.org/proposedrevision/Pages/ BipolarandRelatedDisorders.aspx
38. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet 2009;373: 31-41.
39. Leboyer M, Kupfer DJ. Bipolar disorder: New perspectives in health care and prevention. J Clin Psychiatry 2010;71: 1689-95.
40. Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, et al. [Drawing up guidelines for the attendance of physical health of patients with severe mentalillness]. Encephale 2009;35: 330-9. In French.